Huang, Fenglei <br/><br/>
Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Dec 2008 
 - 4300-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1098-6596 
<br/><br/><label>Standard No.: </label>10.1128/AAC.00363-08  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Anti-HIV Agents--administration & dosage<br/>Area Under Curve<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Humans<br/>Male<br/>Middle Aged<br/>Reverse Transcriptase Inhibitors--administration & dosage<br/>Ritonavir--administration & dosage<br/>Treatment Outcome<br/>Young Adult